Resverlogix Reports Top-Line Results from ASSURE Clinical Trial
Complete the form below to unlock access to ALL audio articles.
Resverlogix Corp. has announced that its Phase 2b ASSURE clinical trial evaluating RVX-208 in high-risk cardiovascular patients with low high-density lipoprotein (HDL) did not meet its primary endpoint of a -0.6% change in percent atheroma volume as determined by intravascular ultrasound (IVUS).
The RVX-208 treated group had -0.4% plaque regression (p= 0.08). RVX-208 is Resverlogix's first-in-class orally active BET-protein inhibitor.
The patient group receiving active treatment met the secondary endpoints of regression of total (coronary) atheroma volume (TAV) and increases in Apolipoprotein A-I (ApoA-I) and HDL cholesterol.
Unexpected strong placebo results will need to be further explored.
ASSURE, a 26-week, multi-center, double-blind, randomized, parallel group, placebo-controlled trial enrolled 324 patients and was led by the Cleveland Clinic.
The secondary endpoints for ASSURE included safety and tolerability of RVX-208, effects of the compound on plasma ApoA-I, HDL cholesterol, HDL-subclasses and non-HDL lipid parameters.
"Together with the study's principal investigators, we remain focused on analyzing the full data set over the coming weeks and months to determine whether continued development of RVX-208 in cardiovascular disease is warranted," said Donald McCaffrey, president and chief executive officer of Resverlogix.